Unlock instant, AI-driven research and patent intelligence for your innovation.

Universal cancer vaccine

An immune adjuvant and telomerase technology, which is applied in the direction of medical preparations containing active ingredients, antibody medical ingredients, transferase, etc., can solve the problem of specific loss of T cells

Inactive Publication Date: 2018-12-21
毛里齐奥扎内蒂
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, some T cell specificity may be lost over time due to senescence and exhaustion, or remodeling of cancer cell immunogenicity through immune editing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Universal cancer vaccine
  • Universal cancer vaccine
  • Universal cancer vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1 - Bladder Cancer Clinical Trial Using B Cells Transfected with a Plasmid Expressing an Altered Telomerase Polypeptide

[0082] Clinical trials in patients with telomerase-specific cancers such as bladder / urothelial carcinoma. The primary efficacy endpoint was percent survival at 24 months after treatment. The method of treatment is a population of B cells transfected with a nucleic acid plasmid encoding an altered telomerase corresponding to SEQ ID NO:28 or 29. Peripheral blood mononuclear cells were isolated from each patient, ex vivo spontaneously transfected with plasmid DNA, and cultured for 24 hours under cell type appropriate culture conditions. After this incubation period, the patient was injected intravenously with 1 x 10 5 up to 5×10 6 own B cells. Patients received a total of three treatments one month apart.

Embodiment 2

[0083] Example 2 - Immunization of Melanoma Patients Using Altered Telomerase Polypeptides

[0084] 1 mg of the altered telomerase polypeptide is administered subcutaneously or intradermally to a melanoma patient. The altered telomerase polypeptide is prepared with an immune adjuvant. Patients received a total of three treatments one month apart.

Embodiment 3

[0085] Example 3 - Immunization of Hepatocellular Carcinoma Patients Using Plasmid DNA Combined with Electroporation

[0086] Using electroporation, 100 micrograms of the plasmid encoding the altered telomerase peptide were administered intradermally at 10 different sites in the patient. A total of 1 mg was administered.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described herein are compositions of matter and methods for treating cancer. The compositions comprise altered human telomerase polypeptides containing T cell epitopes that have been altered to increase immunogenicity. The methods comprise administration of the polypeptides or nucleic acids, such as DNA or RNA encoding the polypeptides, to individuals afflicted with, or at risk of, developing cancer.

Description

[0001] cross reference [0002] This application claims U.S. Application Serial No. 62 / 298,956, filed February 23, 2016, U.S. Application 62 / 320,440, filed April 8, 2016, and U.S. Application 62 / 341,771, filed May 26, 2016 Interest; all of these US applications are hereby incorporated in their entirety. Background technique [0003] Human telomerase reverse transcriptase (TERT) is a constitutive autotumor antigen and a potential target for cancer immunotherapy. In the past, immunotherapy trials targeting TERT have failed to fulfill the promise of TERT as an immunotherapy target. For example, among 25 clinical studies using TERT as an antigen to induce antitumor immune responses, only 2 studies showed objective clinical responses, and even then, the overall response rate was less than 20%. [0004] Telomerase reverse transcriptase (TERT) is a component of telomerase, which synthesizes tandem 5'-TTAGGG-3' outer nucleotides of telomeric DNA by reverse transcription of its own ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K38/16C12N9/12C12Q1/48C07K14/00C07H21/04
CPCA61K39/015A61K39/12A61K2039/6037C12N2710/20034C12N2760/18434C12N2770/24134A61K38/45A61K2239/38A61K39/464457A61K2239/56A61K39/4622A61K2239/31A61K39/4612A61K39/001157A61K39/0005A61K39/39
Inventor 毛里齐奥·扎内蒂
Owner 毛里齐奥扎内蒂